MA44018B1 - Dérivés de tétrahydroisoquinoline - Google Patents

Dérivés de tétrahydroisoquinoline

Info

Publication number
MA44018B1
MA44018B1 MA44018A MA44018A MA44018B1 MA 44018 B1 MA44018 B1 MA 44018B1 MA 44018 A MA44018 A MA 44018A MA 44018 A MA44018 A MA 44018A MA 44018 B1 MA44018 B1 MA 44018B1
Authority
MA
Morocco
Prior art keywords
muscle
troponin
disorders
tetrahydroisoquinoline
treating
Prior art date
Application number
MA44018A
Other languages
English (en)
Other versions
MA44018A (fr
Inventor
Hiroaki Tanaka
Ippei Sato
Takashi Kamikubo
Masanori Miura
Yuji Matsushima
Yasuhiro Shiina
Susumu Yamaki
Tomoyuki Saito
Hiroshi Kiyohara
Munemichi OHE
Kayoko Mihara
Bradley MORGAN
Fady Malik
Scott Collibee
Luke Ashcraft
Pu-Ping Lu
Jeffrey Warrington
Marc Garard
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MA44018A publication Critical patent/MA44018A/fr
Publication of MA44018B1 publication Critical patent/MA44018B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouveaux composés dérivés de la tétrahydroisoquinoline qui peuvent être utilisés à titre de principe actif pour une composition pharmaceutique, et en particulier, pour une composition pharmaceutique utile pour prévenir ou traiter une maladie ou une affection sensible à la modulation de la contractilité du sarcomère squelettique. L'objectif est atteint, par exemple, par modulation du complexe de troponine du sarcomère du muscle squelettique rapide par l'intermédiaire d'un ou de plusieurs des filaments suivants : myosine squelettique rapide, actine, tropomyosine, troponine c, troponine i et troponine t, leurs fragments et isoformes. Les composés dérivés de la tétrahydroisoquinoline peuvent ainsi être utilisés comme agent pour prévenir ou traiter 1) les troubles neuromusculaires, 2) les troubles du muscle volontaire, 3) les troubles du snc dans lesquels la faiblesse, l'atrophie, et la fatigue musculaires sont des symptômes importants, 4) les symptômes musculaires provenant de troubles systémiques, et 5) les dysfonctions du plancher pelvien et du muscle sphincter urétral/anal.
MA44018A 2016-02-12 2017-02-10 Dérivés de tétrahydroisoquinoline MA44018B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
PCT/US2017/017295 WO2017139526A1 (fr) 2016-02-12 2017-02-10 Dérivés de tétrahydroisoquinoline

Publications (2)

Publication Number Publication Date
MA44018A MA44018A (fr) 2018-12-19
MA44018B1 true MA44018B1 (fr) 2022-05-31

Family

ID=59561239

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44018A MA44018B1 (fr) 2016-02-12 2017-02-10 Dérivés de tétrahydroisoquinoline

Country Status (32)

Country Link
US (5) US9914741B2 (fr)
EP (2) EP3413892B1 (fr)
JP (2) JP6832943B2 (fr)
KR (1) KR20180120701A (fr)
CN (2) CN109069498B (fr)
AR (1) AR107592A1 (fr)
AU (1) AU2017217663B2 (fr)
BR (1) BR112018016475A2 (fr)
CA (1) CA3012839A1 (fr)
CL (1) CL2018002287A1 (fr)
CO (1) CO2018007920A2 (fr)
DK (1) DK3413892T3 (fr)
ES (1) ES2913423T3 (fr)
HR (1) HRP20220655T1 (fr)
HU (1) HUE058820T2 (fr)
IL (1) IL261055B (fr)
LT (1) LT3413892T (fr)
MA (1) MA44018B1 (fr)
MD (1) MD3413892T2 (fr)
MX (1) MX2018009759A (fr)
NZ (1) NZ746311A (fr)
PH (1) PH12018501694A1 (fr)
PL (1) PL3413892T3 (fr)
PT (1) PT3413892T (fr)
RS (1) RS63240B1 (fr)
RU (1) RU2743424C2 (fr)
SG (1) SG11201806416XA (fr)
SI (1) SI3413892T1 (fr)
TW (2) TWI719138B (fr)
UA (1) UA124879C2 (fr)
WO (1) WO2017139526A1 (fr)
ZA (1) ZA201804947B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220655T1 (hr) * 2016-02-12 2022-06-24 Cytokinetics, Incorporated Tetrahidroizokinolinski derivati
WO2022099011A1 (fr) 2020-11-06 2022-05-12 Cytokinetics, Inc. 1,4-diazépanones bicycliques et leurs utilisations thérapeutiques

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (fr) 1971-09-16 1974-06-17 Kabi Ab
PL331602A1 (en) * 1996-08-06 1999-08-02 Pfizer Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
IL128994A (en) 1996-09-25 2004-12-15 Zeneca Ltd History of quinoline and naphthyridine and their salts, processes for their preparation, pharmaceutical preparations containing them and their use as medicines
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
WO2001007411A1 (fr) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Derives de biaryluree
JP2001106673A (ja) 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2565018A1 (fr) * 2004-04-28 2005-11-10 Takeda Pharmaceutical Company Limited Derive de quinoline fusionnee et utilisation de celui-ci
AU2006331765A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
PT2583970E (pt) * 2006-08-02 2016-02-08 Cytokinetics Inc Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
MY162052A (en) 2007-01-05 2017-05-31 Daiichi Sankyo Co Ltd Fused substitute aminopyrrolidine derivative
WO2008147547A1 (fr) 2007-05-25 2008-12-04 Amgen Inc. Composés d'hydroxyéthylamine substitués en tant que modulateurs de la bêta-sécrétase et procédés d'utilisation
WO2009108332A1 (fr) * 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. Inhibiteurs de la 11β-hydroxystéroïde déshydrogénase de type 1
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
WO2010038901A1 (fr) * 2008-10-02 2010-04-08 Taisho Pharmaceutical Co., Ltd. Dérivé de 7-pipéridinoalkyle-3,4-dihydroquinolone
MX2011004535A (es) 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
WO2010131146A1 (fr) 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2582698B1 (fr) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) * 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
SG11201406270YA (en) 2012-04-02 2014-10-30 Cytokinetics Inc Methods for improving diaphragm function
EP2836590A4 (fr) 2012-04-11 2016-04-13 Cytokinetics Inc Procédés d'amélioration de la résistance à la fatigue des muscles du squelette
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
HRP20220183T1 (hr) 2014-04-29 2022-04-29 Cytokinetics, Inc. Postupci smanjivanja propadanja vitalnog kapaciteta
PT3192512T (pt) 2014-09-09 2019-10-29 Cytokinetics Inc Nova composição farmacêutica para prevenção e/ou tratamento de incontinência urinária
HRP20220655T1 (hr) * 2016-02-12 2022-06-24 Cytokinetics, Incorporated Tetrahidroizokinolinski derivati

Also Published As

Publication number Publication date
IL261055B (en) 2021-03-25
PT3413892T (pt) 2022-05-30
US20200270266A1 (en) 2020-08-27
ZA201804947B (en) 2024-05-30
CL2018002287A1 (es) 2019-01-04
RU2743424C2 (ru) 2021-02-18
TWI773118B (zh) 2022-08-01
WO2017139526A1 (fr) 2017-08-17
AR107592A1 (es) 2018-05-16
DK3413892T3 (da) 2022-05-23
UA124879C2 (uk) 2021-12-08
BR112018016475A2 (pt) 2018-12-26
NZ746311A (en) 2022-08-26
US9914741B2 (en) 2018-03-13
JP2021073270A (ja) 2021-05-13
SI3413892T1 (sl) 2022-06-30
EP4032877A1 (fr) 2022-07-27
TW201741316A (zh) 2017-12-01
CO2018007920A2 (es) 2018-12-14
RU2018130002A3 (fr) 2020-03-24
SG11201806416XA (en) 2018-08-30
EP3413892A1 (fr) 2018-12-19
EP3413892A4 (fr) 2019-08-14
LT3413892T (lt) 2022-06-10
US10689393B2 (en) 2020-06-23
KR20180120701A (ko) 2018-11-06
US11479561B2 (en) 2022-10-25
WO2017139526A8 (fr) 2018-08-16
MD3413892T2 (ro) 2022-06-30
JP6832943B2 (ja) 2021-02-24
ES2913423T3 (es) 2022-06-02
US20190194220A1 (en) 2019-06-27
CN113666938A (zh) 2021-11-19
RU2018130002A (ru) 2020-03-12
US20230125280A1 (en) 2023-04-27
RS63240B1 (sr) 2022-06-30
HUE058820T2 (hu) 2022-09-28
CN109069498A (zh) 2018-12-21
US20180148458A1 (en) 2018-05-31
PL3413892T3 (pl) 2022-06-13
CA3012839A1 (fr) 2017-08-17
CN109069498B (zh) 2021-08-17
PH12018501694A1 (en) 2019-01-28
MA44018A (fr) 2018-12-19
TWI719138B (zh) 2021-02-21
MX2018009759A (es) 2018-11-29
AU2017217663A1 (en) 2018-10-04
US20170233402A1 (en) 2017-08-17
IL261055A (en) 2018-10-31
EP3413892B1 (fr) 2022-04-20
JP7137650B2 (ja) 2022-09-14
AU2017217663B2 (en) 2021-06-17
US10259821B2 (en) 2019-04-16
JP2019509267A (ja) 2019-04-04
TW202138373A (zh) 2021-10-16
HRP20220655T1 (hr) 2022-06-24

Similar Documents

Publication Publication Date Title
Harris et al. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA42456A (fr) Inhibiteurs de hpk1 et leurs procédés d'utilisation
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
EA200501274A1 (ru) Пиразолы и способы их получения и применения
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
BR0008687A (pt) Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica
MA44018B1 (fr) Dérivés de tétrahydroisoquinoline
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
MA30296B1 (fr) Nouvelles amines
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TW200502221A (en) Novel lactams and uses thereof
DE602005017815D1 (de) Behandlung von entzündlicher darmerkrankung
MA45803B1 (fr) Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
Faturi et al. Intermittent stretching induces fibrosis in denervated rat muscle
Himori et al. Neuromuscular electrical stimulation prevents skeletal muscle dysfunction in adjuvant-induced arthritis rat